ImpactRx Launches Oncology Studies

US-based pharmaceutical data provider ImpactRx has formed a new unit to focus on the fast growing $20bn US oncology market. The new unit has launched ONCLink, a range of services to measure the effects of pharmaceutical promotion and education, and track physician behaviour and treatment decisions.

The various ONCLink products, based on a representative national network of 300 practising oncologists, will make use of ImpactRx's data acquisition technology and its longitudinal promotion and treatment data.

The new unit will be run by Gregory Gallo, as VP and General Manager. Gallo has 20 years of sales, marketing and strategic planning experience in the pharmaceutical and healthcare diagnostic industries.

The company expects the oncology market to grow by 20% this year, and says its clients are increasingly investing in the area. Nancy Lurker, the company's CEO, says 'the escalating demand from both biotech and pharmaceutical companies for data to measure the effectiveness of oncology promotional and educational activities led to ImpactRx's investment in the oncology business unit'.

The company is online at www.impactrx.com.

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• ImpactRx
• All news